.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have introduced a promising approach for liver fibrosis treatment using a novel nanotechnology platform. However, liver fibrosis acts as a dangerous precursor to cirrhosis in patients with chronic liver diseases. Consequently, current clinical options often fail due to systemic side effects or low tissue specificity. Therefore, to overcome these barriers, scientists developed the Lac-AGly nanoparticle system. This platform utilizes natural glycogen as a biodegradable backbone. Notably, researchers modified the glycogen with lactobionic acid to target asialoglycoprotein receptors (ASGPR) on hepatocytes. For instance, this modification ensures that the therapeutic payload reaches the intended site with high precision.
This system delivers small interfering RNA (siRNA) specifically designed to silence connective tissue growth factor (CTGF). Furthermore, the researchers achieved a 51.2% degree of amination on the glycogen backbone. This modification conferred efficient siRNA binding capacity. Specifically, the resulting nanocomplexes maintained a uniform spherical shape and an average particle size of 247.2 nm. Moreover, in vivo testing revealed remarkable results in animal models. In addition, the treatment reduced the collagen-positive area in the liver from 14.3% to just 3.1%. Consequently, this platform demonstrates significant potential for clinical translation. Overall, it offers a safe and effective way to achieve gene-silencing without harming healthy tissues.
The system uses lactobionic acid to recognize asialoglycoprotein receptors (ASGPR). These receptors are primarily expressed on the surface of hepatocytes. Therefore, the siRNA is delivered directly to the liver cells.
Connective tissue growth factor (CTGF) is a key protein that promotes the accumulation of collagen and scar tissue. Specifically, silencing this gene helps halt and reverse the fibrotic process.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a glycogen-based nanoparticle platform that targets hepatocytes to silence CTGF, significantly reducing liver fibrosis in vivo....
6 months ago
Cutaneous leishmaniasis in HIV-coinfected patients presents unique diagnostic and therapeutic challenges, often manifesting as disseminated disease. Effective care requires systemic antileishmanial regimens and immune recovery.
Today
A comprehensive data mining study reveals how online communities discuss cannabis use during pregnancy. Learn why nonexpert advice dominates digital platforms, the maternal-fetal risks of cannabinoids, and how clinicians can proactively address patient queries with evidence-based counseling.
Today
A randomized crossover study demonstrates that the lightweight S-Patch enables extended continuous ECG monitoring exceeding 60 hours in frail older adults with falls, outperforming traditional Holter devices in wear duration and adherence without compromising tolerability or diagnostic efficacy.
Today
A comprehensive analysis of 2,764 trauma registry patients reveals that occupant ejection during rollover crashes increases mortality fourfold. Nonuse of seatbelts escalates ejection risk tenfold, highlighting the urgent need for strict restraint compliance and targeted road-safety interventions.
Today
Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today
